Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

After EUA, US Will Ship Only Half Of Doses For Pfizer, Moderna COVID-19 Vaccines

Executive Summary

Operation Warp Speed will hold back initial shipments to ensure two-dose regimens can be completed; 15 December is ‘chalk’ target date for emergency authorization of Pfizer vaccine, OWS’ Gustave Perna says, calling it only a projection that does not impinge on FDA authority. Sending only half shipments also eases burden on cold shortage capacity at state and local level, he says.

You may also be interested in...



Monkeypox: Bavarian Nordic’s Jynneos Vaccine Should Be Given Only As A Two-Dose Series, US FDA Says

Despite limited vaccine supplies and a growing number of cases, public health officials nix the idea of giving only one dose of Jynneos to individuals exposed or at high risk, saying that two doses one month apart are required for full protection; FDA says it is working to expedite the availability by late July of an additional 786,000 doses made in Denmark.

Possibility Of COVID Vaccine Production Glitches Drives Early US Dose Distribution Plan

Initial allocation plans for the Pfizer/BioNTech vaccine may change after a month or so if manufacturing scaleup proceeds ‘perfectly,’ Operation Warp Speed’s Slaoui suggests.

Last Minute Allocation Shake Up? Pfizer’s One-Dose Data Could Change COVID-19 Vaccine Rollout

New data released ahead of 10 December advisory committee is raising questions about whether the US government’s plan to hold back doses of Pfizer/BioNTech’s vaccine is the right move. Still, most experts don’t expect this to be a one-and-done vaccine. But testing the hypothesis might help the FDA solve its dilemma on when to vaccinate placebo patients.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS143392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel